Moderna
MRNABiological Products, (No Disgnostic Substances) · Avg daily volume 20.7M · fiscal year ends Dec$187.46−15.75−7.75%Volume 18.8M−9% vs avg
10-day20-day50-day200-dayRS line vs S&P 500▲ earnings filed, EPS vs a year agoQ3 EPS due in ~30 days
2026-10-06O 202.09 H 212.22 L 186.64 C 187.46 (−7.75%)Vol 18.8M10 193.8720 172.9350 129.25200 70.04RS line 24.1RS rating 99
| FY (Dec) | EPS $ | Chg | High | Low |
|---|---|---|---|---|
| 2019 | -1.55 | – | – | – |
| 2020 | -1.96 | −27% | – | – |
| 2021 | 28.29 | +1,543% | – | – |
| 2022 | 20.12 | −29% | – | – |
| 2023 | -12.33 | −161% | – | – |
| 2024 | -9.28 | +25% | 170 | 36 |
| 2025 | -7.26 | +22% | 49 | 22 |
| TTM | -7.99 | 212 | 22 |
Ratings & facts
RS Rating99
Days at RS 90+21
Setup checks3 / 3
EPS chg, last qtr+8%
EPS acceleratingno
Sales chg, last qtr+2%
P/E (last 4 qtrs)–
Mkt cap$72.94B
Off 52-wk high-11.7%
Quarterly earnings
Latest filing: 10-Q, 2026-07-31Mar ’24FQ1 ’24
Jun ’24FQ2 ’24
Sep ’24FQ3 ’24
Dec ’24Q4FQ4 ’24
Mar ’25FQ1 ’25
Jun ’25FQ2 ’25
Sep ’25FQ3 ’25
Dec ’25Q4FQ4 ’25
Mar ’26FQ1 ’26
Jun ’26FQ2 ’26
EPS
EPS
−$3.07
−$3.33
$0.03
−$2.89
−$2.52
−$2.13
−$0.51
−$2.11
−$3.40
−$1.97
% chg
−1,716%
+8%
+100%
−607%
+18%
+36%
−1,800%
+27%
−35%
+8%
Sales
167.0M
241.0M
1.86B
966.0M
108.0M
142.0M
1.02B
678.0M
389.0M
145.0M
% chg
−91%
−30%
+2%
−66%
−35%
−41%
−45%
−30%
+260%
+2%
Filed
05/02
08/01
11/07
02/21
05/01
08/01
11/06
02/20
05/01
07/31
EPS growth ≥ 25%0–25%fallingno comparison
Source: SEC EDGAR 10-Q and 10-K filings, loaded the first time a stock is opened and refreshed daily. Q4 = full year minus the first three quarters. Growth from a loss is measured against the size of the loss (−$1 → $2 = +300%). Analyst estimates are not in EDGAR.